Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 21:49:101306.
doi: 10.1016/j.ijcha.2023.101306. eCollection 2023 Dec.

Clinical outcomes and predictors of long-term mortality, hemorrhagic and thromboembolic events in atrial fibrillation patients at different stages of chronic kidney disease: The CRAFT trial

Marek Styczkiewicz  1 , Mateusz Wawrzeńczyk  2 , Michał Peller  2 , Bartosz Krzowski  2 , Cezary Maciejewski  2 , Piotr Lodziński  2 , Leszek Kraj  3 , Grzegorz Opolski  2 , Marcin Grabowski  2 , Paweł Balsam  2
Affiliations

Clinical outcomes and predictors of long-term mortality, hemorrhagic and thromboembolic events in atrial fibrillation patients at different stages of chronic kidney disease: The CRAFT trial

Marek Styczkiewicz et al. Int J Cardiol Heart Vasc. .

Abstract

Background Chronic kidney disease (CKD) coexisting with atrial fibrillation (AF) increases the risk of hemorrhage and ischemia. The study aimed to determine the relationship between different CKD stages and clinical outcomes of patients suffering from both CKD and AF and to determine the predictors of outcome. Methods The data was derived from multicenter CRAFT trial (NCT02987062). We have conducted a retrospective analysis of hospital records of 2663 AF patients divided in three groups according to their estimated glomerular filtration rate (eGFR) which was <30ml/min/1,73 m2 for group I (n=63), ≥30 and <60 ml/min/1,73 m2 for group II (n=947) and ≥60 ml/min/1,73 m2 for group III (n=1653). The primary study endpoint was major adverse event (MAE) during the mean four-year follow-up. Results The highest rate of MAE was observed in group I followed by group II and III. The rate of all-cause death was 60% in group I, 32% in group II and 15% in group III (p<0.001). Bleeding complications occurred in 25% of patients from group I, 23% from group II and 21% from group III (p=0.14). Thromboembolic events occurred in those groups at the rate of 21%, 14% and 12% respectively (p=0.011). The risk of death was 5 times higher in patients with eGFR<30 treated with vitamin K antagonists (VKA) (HR: 5.016, 95% CI: 1.533-16.417; p=0.007). Conclusions AF patients with CKD are at higher risk of MAE and that risk depends on the CKD stage. VKA treatment was linked to a higher mortality in AF patients with the lowest eGFR values.

Keywords: Atrial fibrillation; Bleeding; Chronic kidney disease; Ischemia; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Kaplan-Meier curve for analysis of freedom from ischemia in patients from different study groups; GFR – glomerular filtration rate.
Fig. 2
Fig. 2
Kaplan-Meier curve for analysis of freedom from bleeding in patients from different study groups; GFR – glomerular filtration rate.
Fig. 3
Fig. 3
Kaplan-Meier curve for analysis of survival in patients from different study groups; GFR – glomerular filtration rate.
Fig. 4
Fig. 4
Kaplan-Meier curve for analysis of composite endpoint in patients from different study groups; GFR – glomerular filtration rate.
See this image and copyright information in PMC

References

    1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomstrom-Lundqvist C., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. - PubMed
    1. Kidney Int. 2022;102(5S):S1–S127. - PubMed
    1. Alonso A., Lopez F.L., Matsushita K., Loehr L.R., Agarwal S.K., Chen L.Y., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946–2953. - PMC - PubMed
    1. Ding W.Y., Gupta D., Wong C.F., Lip G.Y.H. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res. 2021;117(4):1046–1059. - PubMed
    1. Boriani G., Laroche C., Diemberger I., Popescu M.I., Rasmussen L.H., Petrescu L., et al. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep. 2016;6:30271. - PMC - PubMed

LinkOut - more resources